PMID- 36602749 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20240305 IS - 1678-4405 (Electronic) IS - 1517-8382 (Print) IS - 1517-8382 (Linking) VI - 54 IP - 1 DP - 2023 Mar TI - Antifungal antibodies present in intravenous immunoglobulin derived from China. PG - 81-92 LID - 10.1007/s42770-022-00894-z [doi] AB - Fungal infections usually occur in immunocompromised patients. Intravenous immunoglobulin (IVIG) has been used as therapeutic interventions for many infectious diseases, but seldom applied in mycosis due to unknown antifungal specificity. This study aims to determine the presence of antifungal antibodies in IVIG. Binding reactivity of IVIG with crude and recombinant antigens of Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans and Talaromyces marneffei were observed in a dose-dependent manner, similar with mixed normal human sera. The antifungal specificity was further confirmed by competitive enzyme-linked immunosorbent assays (ELISA) inhibited by rabbit specific antifungal polyclonal antibodies (PAbs) and homogenous crude antigens with inhibitions of 65.5-87.2% and 73.1-94.2%, respectively. Moreover, IVIG also reacted with fungal glycoproteins (Csa2, Cpl1 and Mp1p) in a dose-dependent way, which was inhibited by specific rabbit PAbs and homogenous antigens with different inhibitions and pulled down 72.8-83.8% of specific antibodies if preabsorption IVIG with Dynabeads(R) coupled with homogenous glycoproteins. These results furthermore verified the antifungal specificity of IVIG. Among four brands of IVIG, there was different antifungal IgG against C. albicans (P < 0.05) and C. neoformans (P < 0.05), while no difference for A. fumigatus (P = 0.086) and T. marneffei (P = 0.057). IVIG contained a significantly higher level of specific IgG for C. albicans than other three fungi (P <0.001). In conclusion, we proved antifungal IgG against C. albicans, A. fumigatus, C. neoformans and T. marneffei present in IVIG, which might be expected to provide a possible immunoregulation choice for mycosis and an evaluation to humoral immunity against fungi. CI - (c) 2023. The Author(s). FAU - Wang, Yanfang AU - Wang Y AUID- ORCID: 0000-0001-7722-8597 AD - Innovation Platform for In Vitro Diagnosis of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. gzwyf2010@163.com. AD - Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. gzwyf2010@163.com. FAU - Liu, Yugu AU - Liu Y AUID- ORCID: 0000-0003-0759-5230 AD - Innovation Platform for In Vitro Diagnosis of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. AD - Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. FAU - Jiang, Susu AU - Jiang S AUID- ORCID: 0000-0002-1189-1238 AD - Innovation Platform for In Vitro Diagnosis of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. AD - Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. FAU - Zhao, Yan AU - Zhao Y AUID- ORCID: 0000-0002-1214-5106 AD - Innovation Platform for In Vitro Diagnosis of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. AD - Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. FAU - Cai, Jianpiao AU - Cai J AD - State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China. FAU - Hao, Wei AU - Hao W AUID- ORCID: 0000-0003-4077-3852 AD - Innovation Platform for In Vitro Diagnosis of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. AD - Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. FAU - Fu, Ning AU - Fu N AUID- ORCID: 0000-0002-0036-7633 AD - Innovation Platform for In Vitro Diagnosis of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. AD - Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. LA - eng PT - Journal Article DEP - 20230105 PL - Brazil TA - Braz J Microbiol JT - Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] JID - 101095924 RN - 0 (Antifungal Agents) RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Antibodies, Fungal) SB - IM MH - Animals MH - Humans MH - Rabbits MH - Antifungal Agents/pharmacology MH - Immunoglobulins, Intravenous MH - *Mycoses/microbiology MH - Candida albicans MH - Aspergillus fumigatus MH - *Cryptococcus neoformans MH - Antibodies, Fungal PMC - PMC9944592 OTO - NOTNLM OT - Aspergillus fumigatus OT - Candida albicans OT - Cryptococcus neoformans OT - IVIG OT - Talaromyces marneffei OT - antifungal antibody COIS- On behalf of all authors, the corresponding author states that there is no conflict of interest. EDAT- 2023/01/06 06:00 MHDA- 2023/02/25 06:00 PMCR- 2023/01/05 CRDT- 2023/01/05 11:20 PHST- 2022/03/31 00:00 [received] PHST- 2022/12/16 00:00 [accepted] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/01/05 11:20 [entrez] PHST- 2023/01/05 00:00 [pmc-release] AID - 10.1007/s42770-022-00894-z [pii] AID - 894 [pii] AID - 10.1007/s42770-022-00894-z [doi] PST - ppublish SO - Braz J Microbiol. 2023 Mar;54(1):81-92. doi: 10.1007/s42770-022-00894-z. Epub 2023 Jan 5.